ERYTECH adds a new product candidate to its Cancer Metabolism development portfolio Post author:admERY Post published:April 9, 2014 Post category:Newsroom ERYTECH announces the addition of a new product development candidate, erymethionase, to the company’s Cancer Metabolism product pipeline. You Might Also Like ERYTECH Pharma announces the oral presentation of very demonstrative results regarding its technology to Induce specific immune tolerance by antigen loaded erythrocytes. September 7, 2012 ERYTECH receives Orphan Drug Designation by the FDA for eryaspase in Acute Myeloid Leukemia April 2, 2014 ERYTECH reports positive Phase 2b data for eryaspase for the treatment of metastatic pancreatic cancer March 27, 2017
ERYTECH Pharma announces the oral presentation of very demonstrative results regarding its technology to Induce specific immune tolerance by antigen loaded erythrocytes. September 7, 2012
ERYTECH receives Orphan Drug Designation by the FDA for eryaspase in Acute Myeloid Leukemia April 2, 2014
ERYTECH reports positive Phase 2b data for eryaspase for the treatment of metastatic pancreatic cancer March 27, 2017